Cargando…

Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters

PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritter, Zsombor, Papp, László, Zámbó, Katalin, Tóth, Zoltán, Dezső, Dániel, Veres, Dániel Sándor, Máthé, Domokos, Budán, Ferenc, Karádi, Éva, Balikó, Anett, Pajor, László, Szomor, Árpád, Schmidt, Erzsébet, Alizadeh, Hussain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216187/
https://www.ncbi.nlm.nih.gov/pubmed/35756658
http://dx.doi.org/10.3389/fonc.2022.820136
_version_ 1784731374061617152
author Ritter, Zsombor
Papp, László
Zámbó, Katalin
Tóth, Zoltán
Dezső, Dániel
Veres, Dániel Sándor
Máthé, Domokos
Budán, Ferenc
Karádi, Éva
Balikó, Anett
Pajor, László
Szomor, Árpád
Schmidt, Erzsébet
Alizadeh, Hussain
author_facet Ritter, Zsombor
Papp, László
Zámbó, Katalin
Tóth, Zoltán
Dezső, Dániel
Veres, Dániel Sándor
Máthé, Domokos
Budán, Ferenc
Karádi, Éva
Balikó, Anett
Pajor, László
Szomor, Árpád
Schmidt, Erzsébet
Alizadeh, Hussain
author_sort Ritter, Zsombor
collection PubMed
description PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed with DLBCL were assessed. The scans were carried out in two clinical centers. Two-year event-free survival (EFS) was defined. After delineation of lymphoma lesions, conventional PET parameters and in vivo radiomics were extracted. For 2-year EFS prognosis assessment, the Center 1 dataset was utilized as the training set and underwent automated machine learning analysis. The dataset of Center 2 was utilized as an independent test set to validate the established predictive model built by the dataset of Center 1. RESULTS: The automated machine learning analysis of the Center 1 dataset revealed that the most important features for building 2-year EFS are as follows: max diameter, neighbor gray tone difference matrix (NGTDM) busyness, total lesion glycolysis, total metabolic tumor volume, and NGTDM coarseness. The predictive model built on the Center 1 dataset yielded 79% sensitivity, 83% specificity, 69% positive predictive value, 89% negative predictive value, and 0.85 AUC by evaluating the Center 2 dataset. CONCLUSION: Based on our dual-center retrospective analysis, predicting 2-year EFS built on imaging features is feasible by utilizing high-performance automated machine learning.
format Online
Article
Text
id pubmed-9216187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92161872022-06-23 Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters Ritter, Zsombor Papp, László Zámbó, Katalin Tóth, Zoltán Dezső, Dániel Veres, Dániel Sándor Máthé, Domokos Budán, Ferenc Karádi, Éva Balikó, Anett Pajor, László Szomor, Árpád Schmidt, Erzsébet Alizadeh, Hussain Front Oncol Oncology PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed with DLBCL were assessed. The scans were carried out in two clinical centers. Two-year event-free survival (EFS) was defined. After delineation of lymphoma lesions, conventional PET parameters and in vivo radiomics were extracted. For 2-year EFS prognosis assessment, the Center 1 dataset was utilized as the training set and underwent automated machine learning analysis. The dataset of Center 2 was utilized as an independent test set to validate the established predictive model built by the dataset of Center 1. RESULTS: The automated machine learning analysis of the Center 1 dataset revealed that the most important features for building 2-year EFS are as follows: max diameter, neighbor gray tone difference matrix (NGTDM) busyness, total lesion glycolysis, total metabolic tumor volume, and NGTDM coarseness. The predictive model built on the Center 1 dataset yielded 79% sensitivity, 83% specificity, 69% positive predictive value, 89% negative predictive value, and 0.85 AUC by evaluating the Center 2 dataset. CONCLUSION: Based on our dual-center retrospective analysis, predicting 2-year EFS built on imaging features is feasible by utilizing high-performance automated machine learning. Frontiers Media S.A. 2022-06-08 /pmc/articles/PMC9216187/ /pubmed/35756658 http://dx.doi.org/10.3389/fonc.2022.820136 Text en Copyright © 2022 Ritter, Papp, Zámbó, Tóth, Dezső, Veres, Máthé, Budán, Karádi, Balikó, Pajor, Szomor, Schmidt and Alizadeh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ritter, Zsombor
Papp, László
Zámbó, Katalin
Tóth, Zoltán
Dezső, Dániel
Veres, Dániel Sándor
Máthé, Domokos
Budán, Ferenc
Karádi, Éva
Balikó, Anett
Pajor, László
Szomor, Árpád
Schmidt, Erzsébet
Alizadeh, Hussain
Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title_full Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title_fullStr Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title_full_unstemmed Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title_short Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
title_sort two-year event-free survival prediction in dlbcl patients based on in vivo radiomics and clinical parameters
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216187/
https://www.ncbi.nlm.nih.gov/pubmed/35756658
http://dx.doi.org/10.3389/fonc.2022.820136
work_keys_str_mv AT ritterzsombor twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT papplaszlo twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT zambokatalin twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT tothzoltan twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT dezsodaniel twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT veresdanielsandor twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT mathedomokos twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT budanferenc twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT karadieva twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT balikoanett twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT pajorlaszlo twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT szomorarpad twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT schmidterzsebet twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters
AT alizadehhussain twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters